Novo Nordisk面临美国关税及投资者诉讼, Novo Nordisk faces US tariffs and investor lawsuits but reports strong profits from its obesity drugs.

丹麦制药公司诺沃·诺迪斯克(Novo Nordisk)正准备为潜在的美国关税做准备, Danish pharmaceutical company Novo Nordisk is preparing for potential US tariffs while facing investor lawsuits over alleged misinformation about a study on its obesity drug. 尽管面临法律挑战,但该公司报告说,由于对Wegovy重量损失疗法的需求增加,该公司在Q4中利润丰厚。 Despite legal challenges, the company reported strong profits in Q4, driven by increased demand for its Wegovy weight-loss therapy. 诺沃·诺迪斯克对其业务仍然充满信心,奥泽姆比克和韦戈维在市场中取得了重大成功。 Novo Nordisk remains confident in its business, with Ozempic and Wegovy seeing significant market success.